{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:41:16Z","timestamp":1793241676760,"version":"4.5.0"},"reference-count":184,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:sec id=\"ab-jsc220007-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Recent advances in treatment and prevention of HIV warrant updated recommendations to guide optimal practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc220007-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Based on a critical evaluation of new data, to provide clinicians with recommendations on use of antiretroviral drugs for the treatment and prevention of HIV, laboratory monitoring, care of people aging with HIV, substance use disorder and HIV, and new challenges in people with HIV, including COVID-19 and monkeypox virus infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc220007-3\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>A panel of volunteer expert physician scientists were appointed to update the 2020 consensus recommendations. Relevant evidence in the literature (PubMed and Embase searches, which initially yielded 7891 unique citations, of which 834 were considered relevant) and studies presented at peer-reviewed scientific conferences between January 2020 and October 2022 were considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc220007-4\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Initiation of antiretroviral therapy (ART) is recommended as soon as possible after diagnosis of HIV. Barriers to care should be addressed, including ensuring access to ART and adherence support. Integrase strand transfer inhibitor\u2013containing regimens remain the mainstay of initial therapy. For people who have achieved viral suppression with a daily oral regimen, long-acting injectable therapy with cabotegravir plus rilpivirine given as infrequently as every 2 months is now an option. Weight gain and metabolic complications have been linked to certain antiretroviral medications; novel strategies to ameliorate these complications are needed. Management of comorbidities throughout the life span is increasingly important, because people with HIV are living longer and confronting the health challenges of aging. In addition, management of substance use disorder in people with HIV requires an evidence-based, integrated approach. Options for preexposure prophylaxis include oral medications (tenofovir disoproxil fumarate or tenofovir alafenamide plus emtricitabine) and, for the first time, a long-acting injectable agent, cabotegravir. Recent global health emergencies, like the SARS-CoV-2 pandemic and monkeypox virus outbreak, continue to have a major effect on people with HIV and the delivery of services. To address these and other challenges, an equity-based approach is essential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc220007-5\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Advances in treatment and prevention of HIV continue to improve outcomes, but challenges and opportunities remain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2022.22246","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T11:32:02Z","timestamp":1669894322000},"page":"63","source":"Crossref","is-referenced-by-count":552,"title":["Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults"],"prefix":"10.1001","volume":"329","author":[{"given":"Rajesh T.","family":"Gandhi","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Bedimo","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer F.","family":"Hoy","sequence":"additional","affiliation":[{"name":"The Alfred Hospital and Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael J.","family":"Landovitz","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen F.","family":"Eaton","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[{"name":"University of Cologne and German Center for Infection Research (DZIF), Bonn-Cologne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut"},{"name":"The Veterans Administration Connecticut Healthcare System, West Haven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Sax","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Thacker & Thompson, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance A.","family":"Benson","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P.","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Public Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"del Rio","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine and Grady Health System, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[{"name":"The University of North Carolina School of Medicine at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[{"name":"University Hospital Zurich and Institute of Medical Virology, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"University of Paris Cit\u00e9, Saint-Louis and Lariboisi\u00e8re Hospitals, Assistance Publique Hopitaux de Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"International Antiviral Society\u2013USA, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Saag","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"16","key":"jsc220007r1","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel.","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"jsc220007r2","first-page":"1193","article-title":"The periodic health examination.","volume":"121","author":"Canadian Task Force on the Periodic Health Examination","year":"1979","journal-title":"Can Med Assoc J"},{"issue":"11","key":"jsc220007r3","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1097\/QAD.0000000000002937","article-title":"Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression.","volume":"35","author":"Pathela","year":"2021","journal-title":"AIDS"},{"issue":"5","key":"jsc220007r4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11908-021-00750-5","article-title":"Evidence regarding rapid initiation of antiretroviral therapy in patients living with HIV.","volume":"23","author":"Michienzi","year":"2021","journal-title":"Curr Infect Dis Rep"},{"issue":"12","key":"jsc220007r5","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1093\/cid\/ciz1213","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study.","volume":"71","author":"Huhn","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"8","key":"jsc220007r6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/hiv.v23.8","article-title":"Early HIV treatment and survival over six years of observation in the ANRS 12249 treatment as prevention trial.","volume":"23","author":"Baisley","year":"2022","journal-title":"HIV Med"},{"issue":"1","key":"jsc220007r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09540121.2019.1695728","article-title":"The impact of the housing status on clinical outcomes and health care utilization among individuals living with HIV.","volume":"33","author":"Stanic","year":"2021","journal-title":"AIDS Care"},{"issue":"11","key":"jsc220007r8","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1080\/09540121.2020.1828799","article-title":"Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study.","volume":"33","author":"Maragh-Bass","year":"2021","journal-title":"AIDS Care"},{"issue":"6","key":"jsc220007r9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/QAD.0000000000003172","article-title":"Strategies to improve HIV care outcomes for people with HIV who are out of care.","volume":"36","author":"Higa","year":"2022","journal-title":"AIDS"},{"issue":"1","key":"jsc220007r11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/cid\/ciaa1174","article-title":"Rapid antiretroviral therapy among individuals with acute and early HIV.","volume":"73","author":"Martin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jsc220007r12","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1093\/jac\/dkac207","article-title":"Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, phase 3 trial.","volume":"77","author":"Ch\u00e9ret","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"jsc220007r13","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/cid\/ciac249","article-title":"Antiretroviral initiation at =800 CD4+ cells\/mm3 associated with lower human immunodeficiency virus reservoir size.","volume":"75","author":"Rasmussen","year":"2022","journal-title":"Clin Infect Dis"},{"key":"jsc220007r14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1086\/529001","article-title":"Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.","volume":"197","author":"Hunt","year":"2008","journal-title":"J Infect Dis"},{"issue":"8","key":"jsc220007r15","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/cid\/ciz442","article-title":"Antiretroviral therapy reduces T-cell activation and immune exhaustion markers in human immunodeficiency virus controllers.","volume":"70","author":"Li","year":"2020","journal-title":"Clin Infect Dis"},{"key":"jsc220007r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100963","article-title":"Antiretroviral therapy for HIV controllers: reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort.","volume":"37","author":"Pla\u00e7ais","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"9","key":"jsc220007r17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/hiv.v21.9","article-title":"Rapid ART start in early HIV infection: time to viral load suppression and retention in care in a London cohort.","volume":"21","author":"Girometti","year":"2020","journal-title":"HIV Med"},{"key":"jsc220007r18","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003373","article-title":"Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV.","author":"Jaschinski","year":"2022","journal-title":"AIDS"},{"key":"jsc220007r19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable HIV viremia in an urban HIV clinic.","author":"Christopoulos","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jsc220007r20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women.","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"jsc220007r21","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/infdis\/jiab576","article-title":"Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate\/emtricitabine for HIV prevention: HPTN 084.","volume":"225","author":"Eshleman","year":"2022","journal-title":"J Infect Dis"},{"key":"jsc220007r22","first-page":"37","article-title":"Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs TDF\/FTC for PrEP [Abstract 96] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Landovitz","year":"2022","journal-title":"Top Antiv Med"},{"issue":"10281","key":"jsc220007r25","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","article-title":"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010\/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"key":"jsc220007r26","first-page":"10","article-title":"Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF [Abstract 30] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Stranix-Chibanda","year":"2022","journal-title":"Top Antiv Med"},{"issue":"9","key":"jsc220007r27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa2200600","article-title":"Dolutegravir in pregnancy as compared with current HIV regimens in the United States.","volume":"387","author":"Patel","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"jsc220007r28","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.v24.7","article-title":"What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? a systematic review and meta-analysis.","volume":"24","author":"Burke","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"jsc220007r31","first-page":"549","article-title":"Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial.","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jsc220007r32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1473-3099(20)30869-0","article-title":"Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.","volume":"21","author":"De Castro","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"jsc220007r33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1473-3099(13)70692-3","article-title":"Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"jsc220007r35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine (DTG\/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non-inferiority TANGO randomized trial.","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"jsc220007r36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial.","author":"Llibre","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"jsc220007r37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials.","volume":"85","author":"van Wyk","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"jsc220007r38","doi-asserted-by":"publisher","first-page":"e2323","DOI":"10.1093\/cid\/ciaa1878","article-title":"Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with human immunodeficiency virus.","volume":"73","author":"Greenberg","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"jsc220007r39","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"jsc220007r40","first-page":"184","article-title":"Archived resistance and response to &lt;40 c\/mL & TND\u2013DTG\/3TC FDC at week 48 in SALSA [Abstract 481] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Underwood","year":"2022","journal-title":"Top Antiv Med"},{"key":"jsc220007r42","first-page":"52","article-title":"A randomized trial of switching treatment-experienced adults from PI\/r to DTG [Abstract 136] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Ombajo","year":"2022","journal-title":"Top Antiv Med"},{"issue":"2","key":"jsc220007r43","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus.","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jsc220007r44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study.","volume":"88","author":"Hagins","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"jsc220007r45","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I.","volume":"36","author":"Sax","year":"2022","journal-title":"AIDS"},{"issue":"3","key":"jsc220007r46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"jsc220007r47","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"issue":"4","key":"jsc220007r48","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials.","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10267","key":"jsc220007r49","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"jsc220007r50","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks.","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav"},{"issue":"11","key":"jsc220007r51","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"issue":"1","key":"jsc220007r52","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz533","article-title":"Clinical outcomes following the use of archived proviral HIV-1 DNA genotype to guide antiretroviral therapy adjustment.","volume":"7","author":"Ellis","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"jsc220007r53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"issue":"3","key":"jsc220007r55","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz060","article-title":"Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis.","volume":"6","author":"Kamelian","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"jsc220007r56","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/cid\/cix542","article-title":"Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus?","volume":"65","author":"Koullias","year":"2017","journal-title":"Clin Infect Dis"},{"key":"jsc220007r57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.eclinm.2019.07.001","article-title":"The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada.","volume":"13","author":"Zhu","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"7","key":"jsc220007r58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219802","article-title":"Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART.","volume":"14","author":"Berenguer","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"jsc220007r59","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/jac\/dkab161","article-title":"Prevalence of genotypic baseline risk factors for cabotegravir???+?rilpivirine failure among ARV-naive patients.","volume":"76","author":"Charpentier","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"jsc220007r60","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/QAD.0000000000000628","article-title":"Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.","volume":"29","author":"Sise","year":"2015","journal-title":"AIDS"},{"issue":"9","key":"jsc220007r61","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1468-1293.2012.01003.x","article-title":"Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria.","volume":"13","author":"Samarawickrama","year":"2012","journal-title":"HIV Med"},{"issue":"11","key":"jsc220007r62","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/pds.4657","article-title":"Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia.","volume":"27","author":"Joshi","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"jsc220007r63","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12882-019-1335-9","article-title":"Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.","volume":"20","author":"Kabor\u00e9","year":"2019","journal-title":"BMC Nephrol"},{"issue":"4","key":"jsc220007r64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1053\/j.ajkd.2016.03.430","article-title":"HIV infection, tenofovir, and urine a1-microglobulin: a cross-sectional analysis in the Multicenter AIDS Cohort Study.","volume":"68","author":"Jotwani","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"jsc220007r65","doi-asserted-by":"publisher","first-page":"e3572","DOI":"10.1093\/cid\/ciaa1391","article-title":"Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America.","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jsc220007r66","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jsc220007r67","doi-asserted-by":"publisher","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study.","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"issue":"7","key":"jsc220007r68","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"8","author":"Ogbuagu","year":"2021","journal-title":"Lancet HIV"},{"issue":"4","key":"jsc220007r69","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.v23.4","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"jsc220007r70","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.v24.4","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study.","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"10","key":"jsc220007r71","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"jsc220007r72","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).","volume":"40","author":"Bischoff","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"10","key":"jsc220007r73","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes.","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jsc220007r74","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/jac\/dkab158","article-title":"Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.","volume":"76","author":"Gonz\u00e1lez-Cord\u00f3n","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"jsc220007r75","doi-asserted-by":"publisher","first-page":"e2153","DOI":"10.1093\/cid\/ciaa1219","article-title":"Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens.","volume":"73","author":"Leonard","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jsc220007r76","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1186\/s12879-021-06479-9","article-title":"Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.","volume":"21","author":"Plum","year":"2021","journal-title":"BMC Infect Dis"},{"key":"jsc220007r77","first-page":"15","article-title":"Trends in myocardial infarction risk by HIV status in 2 US healthcare systems [Abstract 39] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Silverberg","year":"2022","journal-title":"Top Antiv Med"},{"issue":"5","key":"jsc220007r78","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab077","article-title":"Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus.","volume":"8","author":"Nolan","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"jsc220007r79","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac355","article-title":"Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with HIV.","author":"O\u2019Halloran","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"jsc220007r80","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","article-title":"Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women.","volume":"85","author":"Summers","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"jsc220007r81","doi-asserted-by":"publisher","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","article-title":"Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada.","volume":"73","author":"Rebeiro","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jsc220007r82","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/QAI.0000000000002603","article-title":"Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D:A:D study.","volume":"86","author":"Petoumenos","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"jsc220007r83","first-page":"236","article-title":"Week-48 metabolic health after switch to DTG\/3TC vs CAR by baseline regimen: SALSA [Abstract 603] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Hagins","year":"2022","journal-title":"Top Antiv Med"},{"issue":"11","key":"jsc220007r84","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"jsc220007r86","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3018(22)00003-0","article-title":"Delayed presentation of HIV among older individuals: a growing problem.","volume":"9","author":"Justice","year":"2022","journal-title":"Lancet HIV"},{"key":"jsc220007r87","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S2352-3018(22)00067-4","article-title":"Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study.","volume":"9","author":"Lee","year":"2022","journal-title":"Lancet HIV"},{"issue":"8","key":"jsc220007r88","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/hiv.v22.8","article-title":"Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC).","volume":"22","author":"Zhabokritsky","year":"2021","journal-title":"HIV Med"},{"issue":"2","key":"jsc220007r89","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/COH.0000000000000614","article-title":"Antiretroviral therapy in older people with HIV.","volume":"15","author":"Richterman","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"jsc220007r90","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/QAD.0000000000002372","article-title":"Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.","volume":"34","author":"Courlet","year":"2020","journal-title":"AIDS"},{"issue":"3","key":"jsc220007r91","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/jgs.v70.3","article-title":"Polypharmacy in older adults with HIV infection: effects on the brain.","volume":"70","author":"Smith","year":"2022","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"jsc220007r92","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00228-019-02785-z","article-title":"Deprescribing of non-antiretroviral therapy in HIV-infected patients.","volume":"76","author":"Blanco","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"jsc220007r93","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/hiv.v21.8","article-title":"Potentially inappropriate medications in older adults living with HIV.","volume":"21","author":"L\u00f3pez-Centeno","year":"2020","journal-title":"HIV Med"},{"issue":"11","key":"jsc220007r94","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/cid\/ciz792","article-title":"A call to action: the role of antiretroviral stewardship in inpatient practice, a joint policy paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine.","volume":"70","author":"Koren","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jsc220007r95","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac093","article-title":"Geriatric conditions and healthcare utilisation in older adults living with HIV.","volume":"51","author":"Greene","year":"2022","journal-title":"Age Ageing"},{"issue":"9","key":"jsc220007r96","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1089\/aid.2021.0155","article-title":"The impact of frailty on all-cause mortality in patients with HIV infection: a systematic review and meta-analysis.","volume":"38","author":"Liu","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"jsc220007r97","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/cid\/ciab655","article-title":"Higher comorbidity burden predicts worsening neurocognitive trajectories in people with human immunodeficiency virus.","volume":"74","author":"Ellis","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"jsc220007r98","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1097\/QAD.0000000000003230","article-title":"Abnormal cognitive aging in people with HIV: evidence from data integration between two countries\u2019 cohort studies.","volume":"36","author":"Aung","year":"2022","journal-title":"AIDS"},{"key":"jsc220007r99","first-page":"50","article-title":"ACTG A5324: a randomized trial of ART intensification for cognitive impairment in PWH [Abstract 133] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Letendre","year":"2022","journal-title":"Top Antiv Med"},{"issue":"3","key":"jsc220007r100","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/QAD.0000000000003128","article-title":"The shifting age distribution of people with HIV using antiretroviral therapy in the United States.","volume":"36","author":"Althoff","year":"2022","journal-title":"AIDS"},{"issue":"6","key":"jsc220007r101","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/cid\/ciab682","article-title":"Strengths and challenges of various models of geriatric consultation for older adults living with human immunodeficiency virus.","volume":"74","author":"Davis","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"jsc220007r102","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1016\/S2352-3018(22)00009-1","article-title":"How health systems can adapt to a population ageing with HIV and comorbid disease.","volume":"9","author":"Kiplagat","year":"2022","journal-title":"Lancet HIV"},{"issue":"1","key":"jsc220007r103","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1038\/s41467-021-24673-w","article-title":"Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.","volume":"12","author":"Lazarus","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"jsc220007r106","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.v22.11","article-title":"Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.","volume":"22","author":"Shieh","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"jsc220007r107","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/17425255.2020.1752662","article-title":"Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.","volume":"16","author":"Yager","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10337","key":"jsc220007r108","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"jsc220007r109","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"jsc220007r110","first-page":"36","article-title":"CA-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk [Abstract LB95] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.","volume":"30","author":"Eshleman","year":"2022","journal-title":"Top Antiv Med"},{"issue":"2","key":"jsc220007r112","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.2019.22.issue-2","article-title":"Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care.","volume":"22","author":"Krakower","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"jsc220007r113","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/09540121.2018.1533238","article-title":"Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California.","volume":"31","author":"Marcus","year":"2019","journal-title":"AIDS Care"},{"issue":"5","key":"jsc220007r114","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"issue":"15","key":"jsc220007r116","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/QAD.0000000000002716","article-title":"Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.","volume":"34","author":"Wagman","year":"2020","journal-title":"AIDS"},{"key":"jsc220007r117","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1097\/QAI.0000000000000637","article-title":"Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions.","volume":"69","author":"Springer","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"jsc220007r118","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1097\/QAD.0000000000002680","article-title":"Associations between methamphetamine use and lack of viral suppression among a cohort of HIV-positive persons who inject drugs in Hai Phong, Vietnam.","volume":"34","author":"Feelemyer","year":"2020","journal-title":"AIDS"},{"issue":"6","key":"jsc220007r119","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s10461-019-02742-y","article-title":"Changes in days of unhealthy alcohol use and antiretroviral therapy adherence, HIV RNA levels, and condomless sex: a secondary analysis of clinical trial data.","volume":"24","author":"Satre","year":"2020","journal-title":"AIDS Behav"},{"issue":"1","key":"jsc220007r120","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2020.2559","article-title":"Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the National Academies of Sciences, Engineering, and Medicine.","volume":"324","author":"Springer","year":"2020","journal-title":"JAMA"},{"key":"jsc220007r121","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1093\/infdis\/jiz673","article-title":"Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA\u2019s advocacy agenda.","volume":"222","author":"Springer","year":"2020","journal-title":"J Infect Dis"},{"issue":"5","key":"jsc220007r122","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/cid\/ciz299","article-title":"Impact of abstinence and of reducing illicit drug use without abstinence on human immunodeficiency virus viral load.","volume":"70","author":"Nance","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jsc220007r123","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13722-021-00277-z","article-title":"Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.","volume":"16","author":"Hoffman","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"jsc220007r124","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/add.v117.7","article-title":"HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.","volume":"117","author":"Korthuis","year":"2022","journal-title":"Addiction"},{"issue":"6","key":"jsc220007r125","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s10461-021-03543-y","article-title":"Assessing the temporality between transitions onto opioid agonist therapy and engagement with antiretroviral therapy in a cohort of HIV-positive people who use opioids daily.","volume":"26","author":"Mitra","year":"2022","journal-title":"AIDS Behav"},{"issue":"3","key":"jsc220007r126","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/QAD.0000000000002427","article-title":"Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa.","volume":"34","author":"Puryear","year":"2020","journal-title":"AIDS"},{"issue":"8","key":"jsc220007r127","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes.","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"jsc220007r128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"jsc220007r129","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial.","volume":"78","author":"Springer","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"jsc220007r130","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/QAI.0000000000001759","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial.","volume":"79","author":"Springer","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"jsc220007r131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11904-019-00436-7","article-title":"Medications for treatment of opioid use disorder among persons living with HIV.","volume":"16","author":"Fanucchi","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"jsc220007r132","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz539","article-title":"Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases.","volume":"7","author":"Seval","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"jsc220007r133","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s10461-019-02592-8","article-title":"Incentives for viral suppression in people living with HIV: a randomized clinical trial.","volume":"23","author":"Silverman","year":"2019","journal-title":"AIDS Behav"},{"issue":"11","key":"jsc220007r134","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/add.2006.101.issue-11","article-title":"Contingency management for treatment of substance use disorders: a meta-analysis.","volume":"101","author":"Prendergast","year":"2006","journal-title":"Addiction"},{"key":"jsc220007r135","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/1471-2458-10-774","article-title":"Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial.","volume":"10","author":"Menza","year":"2010","journal-title":"BMC Public Health"},{"issue":"1","key":"jsc220007r136","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu114","article-title":"Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men.","volume":"2","author":"Landovitz","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"jsc220007r137","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s10461-020-02988-x","article-title":"The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review.","volume":"25","author":"Mistler","year":"2021","journal-title":"AIDS Behav"},{"issue":"8","key":"jsc220007r138","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s10461-021-03220-0","article-title":"HIV pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges.","volume":"25","author":"Assoumou","year":"2021","journal-title":"AIDS Behav"},{"key":"jsc220007r139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108506","article-title":"Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder.","volume":"132","author":"Beck","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"jsc220007r140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247352","article-title":"Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: results from a multi-city cross-sectional survey.","volume":"16","author":"Belludi","year":"2021","journal-title":"PLoS One"},{"key":"jsc220007r141","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.drugpo.2017.12.003","article-title":"Multiple injections per injection episode: high-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana.","volume":"52","author":"Broz","year":"2018","journal-title":"Int J Drug Policy"},{"key":"jsc220007r142","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109241","article-title":"Safer in care: a pandemic-tested model of integrated HIV\/OUD care.","volume":"231","author":"Eaton","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"jsc220007r143","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103283","article-title":"Linking criminal justice-involved individuals to HIV, hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: progress, gaps, and future directions.","volume":"96","author":"Taweh","year":"2021","journal-title":"Int J Drug Policy"},{"key":"jsc220007r144","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.818054","article-title":"Impact of the COVID-19 pandemic on the UNAIDS six 95% HIV control targets.","volume":"9","author":"Jiang","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"jsc220007r145","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/17441692.2022.2063362","article-title":"Persistent disparities in COVID-19-associated impacts on HIV prevention and care among a global sample of sexual and gender minority individuals.","volume":"17","author":"Santos","year":"2022","journal-title":"Glob Public Health"},{"issue":"10","key":"jsc220007r146","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/cid\/ciab379","article-title":"Transient reductions in human immunodeficiency virus (HIV) clinic attendance and food security during the coronavirus disease 2019 (COVID-19) pandemic for people living with HIV in 4 African countries.","volume":"73","author":"Dear","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jsc220007r147","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S2352-3018(20)30211-3","article-title":"Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.","volume":"7","author":"Jewell","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"jsc220007r148","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/S2352-3018(21)00070-9","article-title":"Overview of SARS-CoV-2 infection in adults living with HIV.","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"issue":"1","key":"jsc220007r149","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/COH.0000000000000659","article-title":"The interplay between HIV and COVID-19: summary of the data and responses to date.","volume":"16","author":"Brown","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"jsc220007r150","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/QAI.0000000000002943","article-title":"SARS-CoV-2 testing and positivity among persons with and without HIV in 6 US cohorts.","volume":"90","author":"Park","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"jsc220007r151","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12916-021-02058-6","article-title":"Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence.","volume":"19","author":"Treskova-Schwarzbach","year":"2021","journal-title":"BMC Med"},{"issue":"11","key":"jsc220007r152","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/S2352-3018(21)00240-X","article-title":"Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.","volume":"8","author":"Nomah","year":"2021","journal-title":"Lancet HIV"},{"issue":"4","key":"jsc220007r153","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/QAI.0000000000002989","article-title":"Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020.","volume":"90","author":"Shapiro","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"jsc220007r154","doi-asserted-by":"publisher","first-page":"e1021","DOI":"10.1093\/cid\/ciaa1793","article-title":"Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in New York City: a population-level analysis of linked surveillance data.","volume":"72","author":"Braunstein","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jsc220007r155","doi-asserted-by":"publisher","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","article-title":"Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019.","volume":"73","author":"Dandachi","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jsc220007r156","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/cid\/ciab648","article-title":"The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV).","volume":"74","author":"Woldemeskel","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jsc220007r157","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/QAD.0000000000003161","article-title":"Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV.","volume":"36","author":"Gonz\u00e1lez de Aledo","year":"2022","journal-title":"AIDS"},{"key":"jsc220007r158","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"issue":"4","key":"jsc220007r159","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0000000000003166","article-title":"Impaired antibody response to COVID-19 vaccination in advanced HIV infection.","volume":"36","author":"Hassold","year":"2022","journal-title":"AIDS"},{"issue":"3","key":"jsc220007r160","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/QAD.0000000000003135","article-title":"High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV\u2014but HIV viremia matters?","volume":"36","author":"Xu","year":"2022","journal-title":"AIDS"},{"issue":"1","key":"jsc220007r161","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS) study.","volume":"75","author":"Haidar","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"26","key":"jsc220007r162","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1016\/j.vaccine.2022.04.090","article-title":"Covid-19 vaccine immunogenicity in people living with HIV-1.","volume":"40","author":"Nault","year":"2022","journal-title":"Vaccine"},{"issue":"3","key":"jsc220007r163","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/v14030651","article-title":"Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1-infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection.","volume":"14","author":"Schmidt","year":"2022","journal-title":"Viruses"},{"issue":"5","key":"jsc220007r164","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3018(22)00041-8","article-title":"Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A\/2B trial.","volume":"9","author":"Madhi","year":"2022","journal-title":"Lancet HIV"},{"issue":"6","key":"jsc220007r165","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15934","article-title":"Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States.","volume":"5","author":"Coburn","year":"2022","journal-title":"JAMA Netw Open"},{"key":"jsc220007r168","article-title":"Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19.","author":"Bhimraj","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"jsc220007r169","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v14030493","article-title":"Factors associated with severe COVID-19 and post-acute COVID-19 syndrome in a cohort of people living with HIV on antiretroviral treatment and with undetectable HIV RNA.","volume":"14","author":"Mazzitelli","year":"2022","journal-title":"Viruses"},{"issue":"10","key":"jsc220007r170","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.7326\/M22-2183","article-title":"Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France.","volume":"175","author":"Ferr\u00e9","year":"2022","journal-title":"Ann Intern Med"},{"issue":"6","key":"jsc220007r171","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/acr2.v4.6","article-title":"Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval.","volume":"4","author":"Loncharich","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"jsc220007r172","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa2207323","article-title":"Monkeypox virus infection in humans across 16 countries\u2014April-June 2022.","volume":"387","author":"Thornhill","year":"2022","journal-title":"N Engl J Med"},{"issue":"10279","key":"jsc220007r176","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0140-6736(21)00395-0","article-title":"Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses.","volume":"397","author":"Sullivan","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"jsc220007r177","doi-asserted-by":"publisher","first-page":"820","DOI":"10.15585\/mmwr.mm7125a2","article-title":"HIV testing before and during the COVID-19 pandemic\u2014United States, 2019-2020.","volume":"71","author":"DiNenno","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"jsc220007r179","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15585\/mmwr.mm7105a2","article-title":"Association between social vulnerability and rates of HIV diagnoses among black adults, by selected characteristics and region of residence\u2014United States, 2018.","volume":"71","author":"Dailey","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"jsc220007r181","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1016\/S2352-3018(21)00127-2","article-title":"Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study.","volume":"8","author":"Schaefer","year":"2021","journal-title":"Lancet HIV"},{"issue":"9","key":"jsc220007r182","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/S2468-2667(20)30183-3","article-title":"Could disparities in PrEP uptake limit the public health benefit?","volume":"5","author":"Keen","year":"2020","journal-title":"Lancet Public Health"},{"issue":"7","key":"jsc220007r183","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/infdis\/jiaa296","article-title":"The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study.","volume":"224","author":"Smith","year":"2021","journal-title":"J Infect Dis"},{"key":"jsc220007r10","volume-title":"Opportunities to Improve Opioid Use Disorder and Infectious Disease Services","author":"National Academies of Sciences Engineering and Medicine","year":"2020"},{"key":"jsc220007r24","author":"Zash","year":"2022"},{"key":"jsc220007r29","author":"Ingle","year":"2015"},{"key":"jsc220007r34","author":"Marcy","year":"2020"},{"key":"jsc220007r41","author":"Marks","year":"2022"},{"key":"jsc220007r54","year":"2020"},{"key":"jsc220007r115","author":"Luetkemeyer","year":"2022"},{"key":"jsc220007r23","unstructured":"Department of Health and Human Services. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. ClinicalInfo. Updated March 17, 2022. Accessed November 9, 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal\/whats-new-guidelines?view=full"},{"key":"jsc220007r30","unstructured":"National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Disease Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Updated September 28, 2022. Accessed November 9, 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections? https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection"},{"key":"jsc220007r85","unstructured":"Semaglutide\u2019s efficacy in achieving weight loss for those with HIV (SWIFT) [NCT04174755]. ClinicalTrials.gov. Accessed November 9, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04174755"},{"key":"jsc220007r104","unstructured":"Syphilis. Centers for Disease Control and Prevention. Updated March 24, 2022. Accessed November 9, 2022. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/syphilis.htm"},{"key":"jsc220007r105","unstructured":"US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States\u20132021 Update: A Clinical Practice Guideline. Centers for Disease Control and Prevention. Published 2021. Accessed July 28, 2022. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2021.pdf"},{"key":"jsc220007r111","unstructured":"National Clinician Consultation Center website. Accessed November 9, 2022. https:\/\/aidsetc.org\/aetc-program\/national-clinician-consulation-center"},{"key":"jsc220007r166","unstructured":"Guidance for COVID-19 and People with HIV. Guidelines Working Groups of the NIH Office of AIDS Research Advisory Council and US Department of Health and Human Services (HHS). Updated February 22, 2022. Accessed July 28, 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/guidance-covid-19-and-people-hiv\/whats-new-covid-19-and-hiv-guidance"},{"key":"jsc220007r167","unstructured":"National Institutes of Health. COVID-19 treatment guidelines. Accessed November 9, 2022. https:\/\/www.covid19treatmentguidelines.nih.gov\/"},{"key":"jsc220007r173","unstructured":"Health Alert Network (HAN). Severe manifestations of monkeypox among people who are immunocompromised due to HIV or other conditions. Published September 29, 2022. Accessed November 1, 2022. https:\/\/emergency.cdc.gov\/han\/2022\/han00475.asp"},{"key":"jsc220007r174","unstructured":"Clinical Info HIV. Guidelines for the use of antretroviral agents in adults and adolescents with HIV. Updated September 1, 2022. Accessed November 9, 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/overview?view=full"},{"key":"jsc220007r175","unstructured":"UNAIDS. 2021 UNAIDS Global AIDS Update: Confronting Inequalities\u2014Lessons for Pandemic Responses From 40 Years of AIDS. Published July 14, 2021. Accessed November 9, 2022. https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021-global-aids-update"},{"key":"jsc220007r178","unstructured":"Centers for Disease Control and Prevention (CDC). Diagnoses of HIV infection in the United States and dependent areas 2020. Accessed November 9, 2022. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance\/vol-33\/index.html"},{"key":"jsc220007r180","unstructured":"HIV\/AIDS Surveillance in Europe 2021: 2020 data. European Centre for Disease Prevention and Control. Published 2021. Accessed November 9, 2022. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/2021-Annual_HIV_Report_0.pdf"},{"key":"jsc220007r184","unstructured":"Political Declaration on HIV and AIDS: Ending Inequalities and Getting on Track to End AIDS by 2030. UNAIDS. Published June 9, 2021. Accessed July 28, 2022. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2021_political-declaration-on-hiv-and-aids_en.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2799240\/jama_gandhi_2022_sc_220007_1671563383.14209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T11:08:47Z","timestamp":1672744127000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2799240"}},"subtitle":["2022 Recommendations of the International Antiviral Society\u2013USA Panel"],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":184,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.22246","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}